EAU 2024热点速递:肌层浸润性膀胱癌的临床进展
Highlights from EAU 2024:the clinical advances in muscle-invasive bladder cancer
王淼 1章小平1
作者信息
- 1. 华中科技大学同济医学院附属协和医院泌尿外科(武汉,430022)
- 折叠
摘要
2024年欧洲泌尿外科协会(EAU)年会于4月5日-8日在法国巴黎召开,展示了全球泌尿外科领域的最新进展.肌层浸润性膀胱癌(muscle-invasive bladder cancer,MIBC)的临床进展主要集中在新辅助免疫治疗与新辅助化疗联合免疫治疗、根治性膀胱切除术中淋巴结清扫术的范围、转移性膀胱癌的治疗进展等3个方面,本文就相关内容作简要介绍.
Abstract
The Annual European Association of Urology(EAU)Congress was held in Paris,France,from A-pril 5th to 8th,2024,showing the latest developments in the field of urology worldwide.The clinical advances in muscle-invasive bladder cancer(MIBC)mainly focus on three aspects:role of neoadjuvant immunotherapy and chemo-immunotherapy,extent of lymphadectomy in radical cystectomy,and the treatment progress in metastatic bladder cancer.This article provides a brief introduction to the relevant contents.
关键词
肌层浸润性膀胱癌/新辅助治疗/免疫治疗/联合治疗Key words
muscle-invasive bladder cancer/neoadjuvant therapy/immunotherapy/combination therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据